CLINICAL CHARACTERISTICS AND PROGNOSTIC FACTORS IN PRIMARY BREAST DIFFUSE LARGE B-CELL LYMPHOMA
Main Article Content
Keywords
Diffuse large B-cell lymphoma, Breast, Prognostic factors, Relapse, Central nervous system
Abstract
Background
Primary breast diffuse large B-cell lymphoma (PB-DLBCL) is a rare subtype of non-Hodgkin lymphoma (NHL) with limited data on the clinical features and prognostic factors.
Patients and Methods
A consecutive cohort of patients with PB-DLBCL was retrospectively analyzed in our hospital from February 1997 through July 2018. The primary endpoint is overall survival (OS) contributing to any cause.
Results
A total of 76 patients were diagnosed with PB-DLBCL. The median age at diagnosis was 51 years (range: 25-80 years), with female prevalence (98.7%). Forty (52.6%) patients had right-sided breast involvement but no bilateral breast involvement at diagnosis. Overall, disease stages IE and IIE were seen in 55 (72.4%) and 21 (27.6%) patients, respectively. According to the stage-modified International Prognostic Index (IPI), 37 (48.7%) patients were classified in the very good risk group (IPI 0). Of the 72 patients available, the non-germinal center B-cell (non-GCB) subtype of DLBCL was observed in 66 (91.6%) patients. All patients received anthracycline-based chemotherapy, 56 (73.7%) with rituximab, 31 (40.8%) also with additional radiation therapy, and 14 (18.4%) patients received a prophylactic intrathecal injection. Seven (9.2%) patients had refractory disease. With a median follow-up of 6.8 years (range 0.4-25.0 years), 10 (13.2%) patients had a relapse in the central nervous system (CNS) site. The 5-year and 10-year OS of all the patients was 97.2% (95% CI: 99.3-89.5) and 84.8% (95% CI: 70.0-93.5), respectively. The median OS was not reached. The median progression-free survival (PFS) was 10.3 years for patients with PB-DLBCL(Figure 2B). The 5-year PFS of all the patients was 76.3% (95% CI: 64.6-84.6). Univariate analysis revealed several prognostic factors, including stage-modified IPI, breast surgery, refractory disease, and CNS relapse. Multivariate analyses produced two independent prognostic factors for patients with PB-DLBCL, including stage-modified IPI score (2-3 versus 0) (hazard ratio: 19.114, 95% CI 1.841 to 198.451, p=0.013) and CNS relapse (hazard ratio: 5.522, 95% CI 1.059 to 28.788, p=0.043).
Conclusion
In our cohort, PB-DLBCL clinical features are similar to prior literature reports. Stage-modified IPI score and CNS relapse were associated with overall survival.
Downloads
Abstract 439
PDF Downloads 432
HTML Downloads 155
References
[2] P.J. Hosein, J.C. Maragulia, M.P. Salzberg, O.W. Press, T.M. Habermann, J.M. Vose, M. Bast, R.H. Advani, R. Tibshirani, A.M. Evens, N. Islam, J.P. Leonard, P. Martin, A.D. Zelenetz, and I.S. Lossos, A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. Br J Haematol 165 (2014) 358-63.https://www.ncbi.nlm.nih.gov/pubmed/24467658
[3] W. Jeanneret-Sozzi, A. Taghian, R. Epelbaum, P. Poortmans, D. Zwahlen, B. Amsler, S. Villette, Y. Belkacémi, T. Nguyen, P. Scalliet, P. Maingon, C. Gutiérrez, P. Gastelblum, M. Krengli, R.A. Raad, M. Ozsahin, and R.-O. Mirimanoff, Primary breast lymphoma: Patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study. BMC Cancer 8 (2008)
[4] G. Ryan, G. Martinelli, M. Kuper-Hommel, R. Tsang, G. Pruneri, K. Yuen, D. Roos, A. Lennard, L. Devizzi, S. Crabb, D. Hossfeld, G. Pratt, M. Dell’Olio, S.P. Choo, R.G. Bociek, J. Radford, S. Lade, A.M. Gianni, E. Zucca, F. Cavalli, and J.F. Seymour, Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Annals of Oncology 19 (2008) 233-241
[5] W.C. Jennings, R.S. Baker, S.S. Murray, C.A. Howard, D.E. Parker, L.F. Peabody, H.M. Vice, W.W. Sheehan, and T.A. Broughan, Primary breast lymphoma: the role of mastectomy and the importance of lymph node status. Ann Surg 245 (2007) 784-9.https://www.ncbi.nlm.nih.gov/pubmed/17457172
[6] G. Ryan, G. Martinelli, M. Kuper-Hommel, R. Tsang, G. Pruneri, K. Yuen, D. Roos, A. Lennard, L. Devizzi, S. Crabb, D. Hossfeld, G. Pratt, M. Dell'Olio, S.P. Choo, R.G. Bociek, J. Radford, S. Lade, A.M. Gianni, E. Zucca, F. Cavalli, J.F. Seymour, and G. International Extranodal Lymphoma Study, Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 19 (2008) 233-41.https://www.ncbi.nlm.nih.gov/pubmed/17932394
[7] P. Validire, M. Capovilla, B. Asselain, Y. Kirova, R. Goudefroye, C. Plancher, A. Fourquet, M. Zanni, P. Gaulard, A. Vincent-Salomon, and D. Decaudin, Primary breast non-Hodgkin's lymphoma: a large single center study of initial characteristics, natural history, and prognostic factors. Am J Hematol 84 (2009) 133-9.https://www.ncbi.nlm.nih.gov/pubmed/19199367
[8] H. Shen, Z. Wei, D. Zhou, Y. Zhang, X. Han, W. Wang, L. Zhang, C. Yang, and J. Feng, Primary extra-nodal diffuse large B-cell lymphoma: A prognostic analysis of 141 patients. Oncol Lett 16 (2018) 1602-1614.https://www.ncbi.nlm.nih.gov/pubmed/30008843
[9] J. Caon, E.S. Wai, J. Hart, C. Alexander, P.T. Truong, L.H. Sehn, and J.M. Connors, Treatment and Outcomes of Primary Breast Lymphoma. Clinical Breast Cancer 12 (2012) 412-419
[10] D. Li, J. Deng, H. He, Y. Bu, F. Peng, X. Tang, B. Wang, Y. Lei, H. Zhang, and P. Xie, Primary breast diffuse large B-cell lymphoma shows an activated B-cell–like phenotype. Annals of Diagnostic Pathology 16 (2012) 335-343
[11] S. Yoshida, N. Nakamura, Y. Sasaki, S. Yoshida, M. Yasuda, H. Sagara, T. Ohtake, S. Takenoshita, and M. Abe, Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype. Modern Pathology 18 (2004) 398-405
[12] H.-Y. Yhim, H.J. Kang, Y.H. Choi, S.J. Kim, W.S. Kim, Y.S. Chae, J.S. Kim, C.W. Choi, S.Y. Oh, H.S. Eom, J.-A. Kim, J.H. Lee, J.-H. Won, H. Shim, J.-J. Lee, H.J. Sung, H.J. Kim, D.H. Lee, C. Suh, and J.-Y. Kwak, Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. BMC Cancer 10 (2010)
[13] A. Thomas, B.K. Link, S. Altekruse, P.A. Romitti, and M.C. Schroeder, Primary Breast Lymphoma in the United States: 1975–2013. JNCI: Journal of the National Cancer Institute 109 (2017)
[14] Y. Jia, C. Sun, Z. Liu, W. Wang, and X. Zhou, Primary breast diffuse large B-cell lymphoma: a population-based study from 1975 to 2014. Oncotarget 9 (2017) 3956-3967
[15] D. Kang, S.E. Yoon, D. Shin, J. Lee, Y.S. Hong, S.K. Lee, J.E. Lee, Y.H. Park, J.S. Ahn, E. Guallar, W.S. Kim, J. Lee, S.J. Kim, and J. Cho, Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study. Blood Cancer Journal 11 (2021)
[16] R. Schmitz, G.W. Wright, D.W. Huang, C.A. Johnson, J.D. Phelan, J.Q. Wang, S. Roulland, M. Kasbekar, R.M. Young, A.L. Shaffer, D.J. Hodson, W. Xiao, X. Yu, Y. Yang, H. Zhao, W. Xu, X. Liu, B. Zhou, W. Du, W.C. Chan, E.S. Jaffe, R.D. Gascoyne, J.M. Connors, E. Campo, A. Lopez-Guillermo, A. Rosenwald, G. Ott, J. Delabie, L.M. Rimsza, K. Tay Kuang Wei, A.D. Zelenetz, J.P. Leonard, N.L. Bartlett, B. Tran, J. Shetty, Y. Zhao, D.R. Soppet, S. Pittaluga, W.H. Wilson, and L.M. Staudt, Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. New England Journal of Medicine 378 (2018) 1396-1407
[17] G.W. Wright, D.W. Huang, J.D. Phelan, Z.A. Coulibaly, S. Roulland, R.M. Young, J.Q. Wang, R. Schmitz, R.D. Morin, J. Tang, A. Jiang, A. Bagaev, O. Plotnikova, N. Kotlov, C.A. Johnson, W.H. Wilson, D.W. Scott, and L.M. Staudt, A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell 37 (2020) 551-568.e14
[18] K. Taniguchi, K. Takata, S.S. Chuang, T. Miyata-Takata, Y. Sato, A. Satou, Y. Hashimoto, M. Tamura, K. Nagakita, N. Ohnishi, M. Noujima-Harada, T. Tabata, Y.Y. Kikuti, Y. Maeda, N. Nakamura, M. Tanimoto, and T. Yoshino, Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma. Am J Surg Pathol 40 (2016) 324-34.https://www.ncbi.nlm.nih.gov/pubmed/26752547
[19] K. Taniguchi, K. Takata, S.-S. Chuang, T. Miyata-Takata, Y. Sato, A. Satou, Y. Hashimoto, M. Tamura, K. Nagakita, N. Ohnishi, M. Noujima-Harada, T. Tabata, Y.Y. Kikuti, Y. Maeda, N. Nakamura, M. Tanimoto, and T. Yoshino, Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma. American Journal of Surgical Pathology 40 (2016) 324-334
[20] R. Chen, D. Zhou, L. Wang, L. Zhu, and X. Ye, MYD88L265P and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy. Therapeutic Advances in Hematology 13 (2022) 204062072110728
[21] W.H. Wilson, R.M. Young, R. Schmitz, Y. Yang, S. Pittaluga, G. Wright, C.-J. Lih, P.M. Williams, A.L. Shaffer, J. Gerecitano, S. de Vos, A. Goy, V.P. Kenkre, P.M. Barr, K.A. Blum, A. Shustov, R. Advani, N.H. Fowler, J.M. Vose, R.L. Elstrom, T.M. Habermann, J.C. Barrientos, J. McGreivy, M. Fardis, B.Y. Chang, F. Clow, B. Munneke, D. Moussa, D.M. Beaupre, and L.M. Staudt, Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nature Medicine 21 (2015) 922-926
[22] H.-Y. Yhim, J.S. Kim, H.J. Kang, S.J. Kim, W.S. Kim, C.W. Choi, H.S. Eom, J.-A. Kim, J.H. Lee, J.H. Won, H. Shim, J. Huh, D.-H. Lee, C. Suh, and J.-Y. Kwak, Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. International Journal of Cancer 131 (2012) 235-243
[23] H.Y. Yhim, D.H. Yoon, S.J. Kim, D.H. Yang, H.S. Eom, K.H. Kim, Y. Park, J.S. Kim, H.J. Kim, C. Suh, W.S. Kim, and J.Y. Kwak, First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial. Cancers (Basel) 12 (2020).https://www.ncbi.nlm.nih.gov/pubmed/32781541
[24] H. Shen, Z. Wei, D. Zhou, Y. Zhang, X. Han, W. Wang, L. Zhang, C. Yang, and J. Feng, Primary extra‑nodal diffuse large B‑cell lymphoma: A prognostic analysis of 141 patients. Oncology Letters (2018)
[25] Y. Sun, L.-M. Xu, X. Chen, D. Qian, J.-Q. You, Z. Yuan, and M. Joks, Diffuse large B-cell lymphoma of the breast: prognostic factors and treatment outcomes. OncoTargets and Therapy (2016) 2069
[26] S. Hu, Y. Song, X. Sun, L. Su, W. Zhang, J. Jia, O. Bai, S. Yang, R. Liang, X. Li, H. Zhang, Y. Gao, W. Zhang, X. Xiao, H. Bao, N. Wang, H. Ren, X. Cen, S.e. Yang, Y. Zhao, Y. Wang, Y. Wang, A. Liu, J. Wang, Y. Shi, M. Yuan, Y. Li, and X. He, Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure. Cancer Science 109 (2018) 3943-3952
[27] X. Sun, B. Xu, Y. Li, J. Du, L. Dong, X. Gao, G. Li, X. Wei, and Y. Song, Primary breast diffuse large B-cell lymphoma-report of 21 cases from China with literatures review. Zhonghua Xue Ye Xue Za Zhi 36 (2015) 853-7.https://www.ncbi.nlm.nih.gov/pubmed/26477765
[28] Y.H. Zhu, W.J. Meng, L.H. He, Y.S. Jia, and Z.S. Tong, Prognosis analysis of primary breast diffuse large B cell lymphoma. Zhonghua Zhong Liu Za Zhi 41 (2019) 235-240.https://www.ncbi.nlm.nih.gov/pubmed/30917462
[29] A. Aviv, T. Tadmor, and A. Polliack, Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options. Ann Oncol 24 (2013) 2236-44.https://www.ncbi.nlm.nih.gov/pubmed/23712546
[30] T.P. Miller, S. Dahlberg, J.R. Cassady, D.J. Adelstein, C.M. Spier, T.M. Grogan, M. LeBlanc, S. Carlin, E. Chase, and R.I. Fisher, Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339 (1998) 21-6.https://www.ncbi.nlm.nih.gov/pubmed/9647875
[31] C.P. Hans, Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 (2004) 275-282
[32] B.D. Cheson, S.J. Horning, B. Coiffier, M.A. Shipp, R.I. Fisher, J.M. Connors, T.A. Lister, J. Vose, A. Grillo-López, A. Hagenbeek, F. Cabanillas, D. Klippensten, W. Hiddemann, R. Castellino, N.L. Harris, J.O. Armitage, W. Carter, R. Hoppe, and G.P. Canellos, Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. Journal of Clinical Oncology 17 (1999) 1244-1244
[33] G.L. Chen, Y. Huang, W. Zhang, X. Pan, W.J. Feng, X.Y. Zhao, X.D. Zhu, W.H. Li, M. Huang, Z.Y. Chen, and W.J. Guo, Three-Tier Prognostic Index in Young Adults With Advanced Gastric Cancer. Front Oncol 11 (2021) 667655.https://www.ncbi.nlm.nih.gov/pubmed/34568007
[34] F. Franco Perez, J. Lavernia, D. Aguiar-Bujanda, J. Miramon, J. Guma, R. Alvarez, J. Gomez-Codina, F.G. Arroyo, M. Llanos, M. Marin, J. Alfaro, C. Quero, M. Delgado, E. Nogales, F. Menarguez, N. Martinez, M. Torrente, A. Royuela, D. Abreu, and M. Provencio, Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group. Clin Lymphoma Myeloma Leuk 17 (2017) 186-191.https://www.ncbi.nlm.nih.gov/pubmed/27847267
[35] P. Radkani, D. Joshi, J.C. Paramo, and T.W. Mesko, Primary breast lymphoma: 30 years of experience with diagnosis and treatment at a single medical center. JAMA Surg 149 (2014) 91-3.https://www.ncbi.nlm.nih.gov/pubmed/24257833
[36] H.Y. Yhim, H.J. Kang, Y.H. Choi, S.J. Kim, W.S. Kim, Y.S. Chae, J.S. Kim, C.W. Choi, S.Y. Oh, H.S. Eom, J.A. Kim, J.H. Lee, J.H. Won, H. Shim, J.J. Lee, H.J. Sung, H.J. Kim, D.H. Lee, C. Suh, and J.Y. Kwak, Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. BMC Cancer 10 (2010) 321.https://www.ncbi.nlm.nih.gov/pubmed/20569446
[37] Y. Jia, C. Sun, Z. Liu, W. Wang, and X. Zhou, Primary breast diffuse large B-cell lymphoma: a population-based study from 1975 to 2014. Oncotarget 9 (2018) 3956-3967.https://www.ncbi.nlm.nih.gov/pubmed/29423097
[38] S. Fukuhara, T. Watanabe, W. Munakata, M. Mori, D. Maruyama, S.W. Kim, Y. Kobayashi, H. Taniguchi, A.M. Maeshima, R. Tanosaki, Y. Matsuno, and K. Tobinai, Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution. Eur J Haematol 87 (2011) 434-40.https://www.ncbi.nlm.nih.gov/pubmed/21740461
[39] G.L. Chen, L. Guo, S. Yang, and D.M. Ji, Cancer risk in tuberculosis patients in a high endemic area. BMC Cancer 21 (2021) 679.https://www.ncbi.nlm.nih.gov/pubmed/34107921
[40] G. Li, G.L. Chen, Y. Zhou, G.Q. Yao, S. Yang, and D.M. Ji, Increased Risk of Lymphoma in Men or the Elderly Infected with Tuberculosis. Mediterr J Hematol Infect Dis 13 (2021) e2021053.https://www.ncbi.nlm.nih.gov/pubmed/34527205
[41] G.L. Chen, Z.G. Xia, J. Jin, B.H. Yu, and J. Cao, Characterization of Artificial Pneumothorax-Unrelated Pyothorax-Associated Lymphoma. J Oncol 2021 (2021) 3869438.https://www.ncbi.nlm.nih.gov/pubmed/33564306
[42] C. Dendle, M. Gilbertson, T. Spelman, R.L. Stuart, T.M. Korman, K. Thursky, S. Opat, and Z. McQuilten, Infection is an Independent Predictor of Death in Diffuse Large B Cell Lymphoma. Sci Rep 7 (2017) 4395.https://www.ncbi.nlm.nih.gov/pubmed/28667319
[43] S. Lanini, A.C. Molloy, P.E. Fine, A.G. Prentice, G. Ippolito, and C.C. Kibbler, Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med 9 (2011) 36.https://www.ncbi.nlm.nih.gov/pubmed/21481281
[44] T.A. Eyre, W. Wilson, A.A. Kirkwood, J. Wolf, C. Hildyard, H. Plaschkes, J. Griffith, P. Fields, A. Gunawan, R. Oliver, S. Booth, J. Kothari, C.P. Fox, N. Martinez-Calle, A. McMillan, M. Bishton, G.P. Collins, and C.S.R. Hatton, Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP. Blood Adv 5 (2021) 2229-2236.https://www.ncbi.nlm.nih.gov/pubmed/33890978
[45] X. Rong, H. Wang, J. Ma, S. Pan, H. Wang, S. Jing, Y. Su, L. Wang, and C. Zhao, Chronic hepatitis B virus infection is associated with a poorer prognosis in diffuse large B-cell lymphoma: a meta-analysis and systemic review. J Cancer 10 (2019) 3450-3458.https://www.ncbi.nlm.nih.gov/pubmed/31293649
[46] M.M. Al-Mansour, S.A. Alghamdi, M.A. Alsubaie, A.A. Alesa, and M.A. Khan, Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma. Infect Agent Cancer 13 (2018) 18.https://www.ncbi.nlm.nih.gov/pubmed/29977329
[47] H.H. Huang, F.Y. Hsiao, H.M. Chen, C.Y. Wang, and B.S. Ko, Antiviral prophylaxis for hepatitis B carriers improves the prognosis of diffuse large B-cell lymphoma in Taiwan - a population-based study. Br J Haematol 192 (2021) 110-118.https://www.ncbi.nlm.nih.gov/pubmed/33131074
[48] R.N. Miranda, T.N. Aladily, H.M. Prince, R. Kanagal-Shamanna, D. de Jong, L.E. Fayad, M.B. Amin, N. Haideri, G. Bhagat, G.S. Brooks, D.A. Shifrin, D.P. O'Malley, C.Y. Cheah, C.E. Bacchi, G. Gualco, S. Li, J.A. Keech, Jr., E.P. Hochberg, M.J. Carty, S.E. Hanson, E. Mustafa, S. Sanchez, J.T. Manning, Jr., Z.Y. Xu-Monette, A.R. Miranda, P. Fox, R.L. Bassett, J.J. Castillo, B.E. Beltran, J.P. de Boer, Z. Chakhachiro, D. Ye, D. Clark, K.H. Young, and L.J. Medeiros, Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol 32 (2014) 114-20.https://www.ncbi.nlm.nih.gov/pubmed/24323027
[49] P.P. Liu, K.F. Wang, J.T. Jin, X.W. Bi, P. Sun, Y. Wang, H. Yang, Z.M. Li, W.Q. Jiang, and Y. Xia, Role of radiation therapy in primary breast diffuse large B-cell lymphoma in the Rituximab era: a SEER database analysis. Cancer Med 7 (2018) 1845-1851.https://www.ncbi.nlm.nih.gov/pubmed/29624913
[50] W. Haque, B. Dabaja, A. Tann, M. Khan, S. Szeja, E.B. Butler, and B.S. Teh, Changes in treatment patterns and impact of radiotherapy for early stage diffuse large B cell lymphoma after Rituximab: A population-based analysis. Radiother Oncol 120 (2016) 150-5.https://www.ncbi.nlm.nih.gov/pubmed/27373911
[51] N. Zhang, C. Cao, Y. Zhu, P. Liu, L. Liu, K. Lu, J. Luo, and N. Zhou, Primary breast diffuse large B-cell lymphoma in the era of rituximab. Onco Targets Ther 9 (2016) 6093-6097.https://www.ncbi.nlm.nih.gov/pubmed/27785056
[52] S. Yoshida, N. Nakamura, Y. Sasaki, S. Yoshida, M. Yasuda, H. Sagara, T. Ohtake, S. Takenoshita, and M. Abe, Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype. Mod Pathol 18 (2005) 398-405.https://www.ncbi.nlm.nih.gov/pubmed/15492762
[53] A. Aviles, N. Neri, and M.J. Nambo, The role of genotype in 104 cases of diffuse large B-cell lymphoma primary of breast. Am J Clin Oncol 35 (2012) 126-9.https://www.ncbi.nlm.nih.gov/pubmed/21325938
[54] H. Nyman, E. Jantunen, E. Juvonen, E. Elonen, J. Bohm, V.M. Kosma, G. Enblad, M.L. Karjalainen-Lindsberg, and S. Leppa, Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma. Bone Marrow Transplant 42 (2008) 93-8.https://www.ncbi.nlm.nih.gov/pubmed/18391989
[55] N. Patil, and M. Girgis, Outcome of germinal center B-cell type compared to non-germinal center/activated B-cell type diffuse large b-cell lymphoma as determined by immunohistochemistry using the Hans algorithm. Journal of Clinical Oncology 38 (2020) e20076-e20076
[56] F. Franco, J. Gonzalez-Rincon, J. Lavernia, J.F. Garcia, P. Martin, C. Bellas, M.A. Piris, L. Pedrosa, J. Miramon, J. Gomez-Codina, D. Rodriguez-Abreu, I. Machado, C. Illueca, J. Alfaro, M. Provencio, and M. Sanchez-Beato, Mutational profile of primary breast diffuse large B-cell lymphoma. Oncotarget 8 (2017) 102888-102897.https://www.ncbi.nlm.nih.gov/pubmed/29262531
[57] X.X. Cao, J. Li, H. Cai, W. Zhang, M.H. Duan, and D.B. Zhou, Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations. Ann Hematol 96 (2017) 1867-1871.https://www.ncbi.nlm.nih.gov/pubmed/28803429
[58] S. Hu, Y. Song, X. Sun, L. Su, W. Zhang, J. Jia, O. Bai, S. Yang, R. Liang, X. Li, H. Zhang, Y. Gao, W. Zhang, X. Xiao, H. Bao, N. Wang, H. Ren, X. Cen, S. Yang, Y. Zhao, Y. Wang, Y. Wang, A. Liu, J. Wang, Y. Shi, M. Yuan, Y. Li, and X. He, Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure. Cancer Sci 109 (2018) 3943-3952.https://www.ncbi.nlm.nih.gov/pubmed/30302857
[59] T. Wen, J. Wang, Y. Shi, H. Qian, and P. Liu, Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances. Leukemia 35 (2020) 312-332